Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P00734
UPID:
THRB_HUMAN
Alternative names:
Coagulation factor II
Alternative UPACC:
P00734; B2R7F7; B4E1A7; Q4QZ40; Q53H04; Q53H06; Q69EZ7; Q7Z7P3; Q9UCA1
Background:
Prothrombin, also known as Coagulation factor II, plays a pivotal role in the coagulation system by converting fibrinogen to fibrin, which is essential for clot formation. It activates several key factors in the coagulation cascade, including factors V, VII, VIII, XIII, and protein C, highlighting its central role in blood homeostasis, inflammation, and wound healing.
Therapeutic significance:
Given its crucial role in blood coagulation, Prothrombin is directly linked to several disorders, including Factor II deficiency, Ischemic stroke, Thrombophilia due to thrombin defect, and recurrent Pregnancy loss. Targeting Prothrombin's function or its genetic variants offers a promising avenue for therapeutic interventions in these conditions.